These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
39 related articles for article (PubMed ID: 18710452)
1. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek]. Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610 [TBL] [Abstract][Full Text] [Related]
2. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22. Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780 [TBL] [Abstract][Full Text] [Related]
3. Can blood tests detect cancer early? Health News; 2002 May; 8(5):4. PubMed ID: 12132407 [No Abstract] [Full Text] [Related]
7. The mechanism and clinical applications of the NMP22 tumor marker immunoassay: a review. Sawczuk IS; Lee B Am Clin Lab; 1999 Apr; 18(3):24-6. PubMed ID: 10538149 [No Abstract] [Full Text] [Related]
8. Telomerase and other novel approaches to bladder cancer detection. Bennett A Clin Lab Sci; 2008; 21(3):185-90; quiz 191-2, following 192. PubMed ID: 18678141 [TBL] [Abstract][Full Text] [Related]
9. Potential of urinary biomarkers in early bladder cancer diagnosis. Lam T; Nabi G Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019 [TBL] [Abstract][Full Text] [Related]
10. Ancillary methods for the detection of recurrent urothelial neoplasia. Ross JS; Cohen MB Cancer; 2000 Apr; 90(2):75-86. PubMed ID: 10794156 [No Abstract] [Full Text] [Related]